Pharma Strategy Blog

Commentary on Pharma & Biotech Oncology / Hematology New Product Development

After attending numerous basic research and clinical updates at the American Urologic Association (AUA) annual meeting in Washington DC, it is clear that the new and emerging therapies are not going to stop at the three grand crus from 2010.

Recently, abiraterone acetate (Zytiga) was approved, but there are a number of critical issues that need to considered, including:

  1. Sequencing
  2. Combinations
  3. Cost
  4. Patient selection

As we learn more about the molecular mechanisms behind resistance to androgen receptor signaling (up and downstream) and new targets emerge, so it may be possible to improve patient outcomes in castration-resitant prostate cancer.

Here’s a short video update of what I thought was interesting here at the conference:

3 Responses to “A vlog update on advanced prostate cancer from the AUA 2011 meeting”

  1. Llarena Anibal

    me gustaria que me indicaras como hacer para conseguir Xytiga, somos de argentina pero vamos a EE.UU en algunas oportunidades , si me puedes ayudar te lo agradeceria

Comments are closed.

error: Content is protected !!